Skip to main content
. 2020 Oct 11;12(10):956. doi: 10.3390/pharmaceutics12100956

Figure 5.

Figure 5

Impact of Blank EMLs, FBX-R, or optimized FBX-EMLs treatments on HCT 116 cell cycle phases. Data are the mean of 4 independent experiments ± SD. * Significantly different vs. Control (p < 0.05); # Significantly different vs. Blank EMLs (p < 0.05); Φ Significantly different vs. FBX-R (p < 0.05).